Home > Publications database > ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. > print

001     181935
005     20240229145701.0
024 7 _ |a 10.1002/1878-0261.13318
|2 doi
024 7 _ |a pmid:36181342
|2 pmid
024 7 _ |a 1574-7891
|2 ISSN
024 7 _ |a 1878-0261
|2 ISSN
024 7 _ |a altmetric:138429307
|2 altmetric
037 _ _ |a DKFZ-2022-02305
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rösch, Lisa
|0 P:(DE-He78)11a5984ad9d927df64e2bd688545375f
|b 0
|e First author
|u dkfz
245 _ _ |a ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein.
260 _ _ |a Hoboken, NJ
|c 2023
|b John Wiley & Sons, Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1673353068_25367
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B310#LA:B310# / 2023 Jan;17(1):37-58
520 _ _ |a Chemotherapy resistance is a persistent clinical problem in relapsed high-risk neuroblastomas. We tested a panel of 15 drugs for sensitization of neuroblastoma cells to the conventional chemotherapeutic vincristine, identifying tariquidar, an inhibitor of the transmembrane pump P-glycoprotein (P-gp/ABCB1), and the ERBB family inhibitor afatinib as the top resistance breakers. Both compounds were efficient in sensitizing neuroblastoma cells to vincristine in trypan blue exclusion assays and in inducing apoptotic cell death. The evaluation of ERBB signaling revealed no functional inhibition, i.e., dephosphorylation of the downstream pathways upon afatinib treatment but direct off-target interference with P-gp function. Depletion of ABCB1, but not ERRB4, sensitized cells to vincristine treatment. P-gp inhibition substantially broke vincristine resistance in vitro and in vivo (zebrafish embryo xenograft). The analysis of gene expression datasets of more than 50 different neuroblastoma cell lines (primary and relapsed) and more than 160 neuroblastoma patient samples from the pediatric precision medicine platform INFORM (Individualized Therapy For Relapsed Malignancies in Childhood) confirmed a pivotal role of P-gp specifically in neuroblastoma resistance at relapse, while the ERBB family appears to play a minor part.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a apoptotic cell death
|2 Other
650 _ 7 |a chemotherapy resistance
|2 Other
650 _ 7 |a off-target
|2 Other
650 _ 7 |a pediatric patient samples
|2 Other
650 _ 7 |a precision medicine
|2 Other
650 _ 7 |a zebrafish xenograft model
|2 Other
700 1 _ |a Herter, Sonja
|0 P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd
|b 1
|u dkfz
700 1 _ |a Najafi, Sara
|0 P:(DE-He78)f08873535c440e3ce033c84d5786f70f
|b 2
|u dkfz
700 1 _ |a Ridinger, Johannes
|0 P:(DE-He78)53112ef656923758316e7079710bc988
|b 3
|u dkfz
700 1 _ |a Peterziel, Heike
|0 P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e
|b 4
|u dkfz
700 1 _ |a Cinatl, Jindrich
|b 5
700 1 _ |a Jones, David T W
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 6
|u dkfz
700 1 _ |a Michaelis, Martin
|b 7
700 1 _ |a Witt, Olaf
|0 P:(DE-He78)143af26de9d57bf624771616318aaf7c
|b 8
|u dkfz
700 1 _ |a Oehme, Ina
|0 P:(DE-He78)908367a659dea9e28dac34592b3c46e5
|b 9
|e Last author
|u dkfz
773 _ _ |a 10.1002/1878-0261.13318
|g p. 1878-0261.13318
|0 PERI:(DE-600)2322586-5
|n 1
|p 37-58
|t Molecular oncology
|v 17
|y 2023
|x 1574-7891
909 C O |p VDB
|o oai:inrepo02.dkfz.de:181935
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)11a5984ad9d927df64e2bd688545375f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)ea170691ed65b95f10820c4c61d6e2cd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)f08873535c440e3ce033c84d5786f70f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)53112ef656923758316e7079710bc988
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)143af26de9d57bf624771616318aaf7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)908367a659dea9e28dac34592b3c46e5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL ONCOL : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-01-06T16:01:33Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-01-06T16:01:33Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-01-06T16:01:33Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL ONCOL : 2022
|d 2023-10-25
920 2 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 2
920 0 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21